CN1451382A - Medicine for treating senile dementia and preparing process thereof - Google Patents
Medicine for treating senile dementia and preparing process thereof Download PDFInfo
- Publication number
- CN1451382A CN1451382A CN 03121979 CN03121979A CN1451382A CN 1451382 A CN1451382 A CN 1451382A CN 03121979 CN03121979 CN 03121979 CN 03121979 A CN03121979 A CN 03121979A CN 1451382 A CN1451382 A CN 1451382A
- Authority
- CN
- China
- Prior art keywords
- medicine
- extract
- diluent
- lubricant
- bilobalide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medicine contg. gingko extract for treating senile dementia and its preparing process are disclosed.
Description
[technical field]
The present invention relates to a kind of medicine for the treatment of senile dementia disease, specifically, the present invention relates to a kind of medicine that contains the treatment senile dementia disease of Folium Ginkgo extract.
[background technology]
Senile dementia is a common complaint among the elderly, and consequence is serious, in some developed countries, has been the 4th of old people's cause of death.Because the characteristics of primary disease are cognitive, dysmnesia, the course of disease is longer, so be not only serious medical care problem, also can cause serious social concern.
The same aging society of having stepped into of China with many countries in the world today.According to statistics, obviously the dement accounts for 2-5% in the old people of over-65s, the person accounts for 15-20% more than 80 years old, as add that light, moderate merges, estimation will be above 2-3 times more than of above-mentioned numeral, senile dementia mainly comprise alzheimer disease (being dementia of the Alzheimer type Senile Dementia of theAlzheimer Type.SDAT), Vascular dementia (Vascular Dementia, VD) and the mixed type dementia.
Cholinesterase inhibitor, cerebral vasodilator, cerebral metabolism and nootropics treatment are mainly adopted in the treatment of relevant senile dementia disease, doctor trained in Western medicine.Alzheimer disease is a common complaint among the elderly, and consequence is serious, in some developed countries, has been the 4th of old people's cause of death.Except that seeking new treatment approach, actual available at present directly effective Therapeutic Method mainly is exactly a cholinesterase inhibitor in the world.Though this kind Therapeutic Method has certain clinical efficacy, the cholinergic system beyond the brain is also had certain influence, so side effect is more, what have also has tangible hepatotoxicity.
Folium Ginkgo involved in the present invention is a higher plant, spermatophyta, and Gymnospermae, Ginkgoaceae GinKgo aceae, Semen Ginkgo GinKgo biloba L (deciduous tree) is seven, the August green leaf of plucking gained after drying.
Sweet, bitter, puckery, the flat GUIXIN of Folium Ginkgo nature and flavor, lung, large intestine channel.
The medicine commonly used that Folium Ginkgo is blood circulation promoting and blood stasis dispelling, astringe the lung and relieving asthma.Semen Ginkgo starts from the Ming Dynasty as medicinal.The Ming Dynasty cures mainly and bigger additional development is arranged the effect of this product so far later on.
In Ancient Times in China, people just find that Folium Ginkgo extract can increase people's cerebral blood circulation, make the refreshed and slow down aging of people.
Many Folium Ginkgo extract that studies have shown that can influence central nervous system function (people " Pharmacol Biochem.Behav. " such as Porsolt R.D., nineteen ninety, the 36th phase, the 963rd page), promote big cerebral circulation metabolism (people such as Karcher L., " Naunyn-Schmiedebe-rg ' s ArchPharmacol ", 1984; The 327th phase: the 31st page), improve memory function (people such as Subham z., " Int.J.Clin.Pharmacol Res. ", 1984 years; The 4th phase: the 89th page).Bilobalide is one group of terpenoid (trip pine, " Shenyang Pharmacy College's journal ", 1988 of having than strong biological activity; The 5 (2): the 142nd page), be called as platelet activating factor antagonist.However, but up to now the Folium Ginkgo terpene lactones extract does not also form a kind of medicine that can treat senile dementia disease.
Therefore, the present invention according to the traditional Chinese medical science about elderly dementia's disease deficiency in origin and excess in superficiality, it is that kidney qi decline causes deficiency of marrow-reservoir, cause that blood stasis, expectorant are turbid to be the target theory, but but but to have made two kinds of products by the Chinese medicine effective component of ginkgo leaf-Folium Ginkgo terpene lactones that extracts blood circulation promoting and blood stasis dispelling be silver capsule, silver diaphragm, and this product carried out many-sided preclinical study, studies have shown that, but but this silver capsule, silver diaphragm are that a kind of toxic and side effects is very low, the new Chinese medicine of determined curative effect.
[summary of the invention]
[goal of the invention]
The objective of the invention is to overcome the defective that exists in the foregoing prior art, proposing a kind of is the medicine of active component with the bilobalide extract, this medicine cures mainly that blood stasis due to qi deficiency, venation are smooth, hypophrenia due to the deficiency of marrow-reservoir, headache brain are dizzy, lip is dark and gloomy, look quietly, few vigorously of few words, or diseases such as restlessness, speech disturbance, inarticulateness.
[technical scheme]
Modern The experimental results shows that Folium Ginkgo and Folium Ginkgo terpene lactones extract thereof can improve brain blood circulation and brain metabolism, improve memory function, influence the cholinergic nerve of maincenter.Cerebral blood flow increasing amount and brain energy metabolism when improving anoxia.Through inventor's number of research projects, determined that the Folium Ginkgo extract active component adds other adjuvant and can prepare medicine of the present invention now.During different dosage form in the required various conventional adjuvant,, be prepared into any peroral dosage form commonly used with the method for Chinese medicinal of routine, as pill, powder, tablet, capsule, oral liquid etc. as diluent, binding agent, disintegrating agent, lubricant etc.
The present invention treats the capsule medicine of senile dementia, it is characterized in that this capsule medicine forms (by weight) by following component:
Bilobalide extract 5-7 part
Diluent 5-8 part
Binding agent 7-9 part
Lubricant 0.05-0.15 part
Preferably, this capsule medicine is formed (by weight) by following component:
6 parts of bilobalide extracts
6 parts of diluent
8 parts of binding agents
0.1 part of lubricant
The present invention treats the tablet medicine of senile dementia, it is characterized in that this tablet medicine forms (by weight) by following component:
Bilobalide extract 5-7 part
Diluent 8-12 part
Binding agent 1-3 part
Disintegrating agent 1-3 part
Lubricant 0.05-0.15 part
Preferably, this tablet medicine is formed (by weight) by following component:
6 parts of bilobalide extracts
10 parts of diluent
2 parts of binding agents
2 parts of disintegrating agents
0.1 part of lubricant
Treat in the medicine of senile dementia in the present invention, described bilobalide extract is according to comprising that the method for following each processing step obtains:
(1) exsiccant ginkgo leaf powder is broken to sheet, place in the reflux, extract, jar, add concentration 40-60 volume % ethanol, its alcoholic solution consumption be make a living by weight dose 5-10 doubly, temperature 75-85 ℃ of following reflux, extract, 3-5 time, each 1-3 hour, need to filter after each the extraction, the merging of these filtrates obtains extracting solution.
(2) described extracting solution≤-0.065Mpa pressure under concentrating under reduced pressure, reclaim its ethanol, this concentrating until the concentrated solution that obtains not having alcohol.
(3) add deionized water and return molten above-mentioned concentrated solution, return molten solution amount and generally be make a living by weight dose 6-10 doubly, return the molten solution left standstill that obtains, filtration.
(4) medicinal liquid that obtains after filtering adsorbs the weight ratio of crude drug amount and resin demand=1: 0.8-2.0, this precious grace chemical plant, Cangzhou, resin effluent north company limited production with the flow velocity of 1-1.5 times of column volume per hour by nonpolar class macroporous resin column.The absorption back then, with the about 10-20 volume of about 2-6 times column volume % ethanol water eluting, discards eluent earlier with 1-4 times of column volume deionized water rinsing, and reuse 2-5 times column volume 60 volume % ethanol water eluting are collected this eluent.
(5) with the eluent collected≤-be evaporated to the extractum that does not have alcohol under the 0.065Mpa pressure, add ethyl acetate extraction 2-5 time then, adding the ethyl acetate total amount is in 0.5-1.0 times of volume of crude drug amount, the combined ethyl acetate extract, reuse mineral acid or organic acid sodium salt solution washing or do not wash.Described mineral acid sodium salt is sodium sulfite, Chile saltpeter, sodium dihydrogen phosphate etc., and described organic acid sodium salt is sodium acetate, sodium citrate, Disodium oxalate. etc.
(6) acetic acid ethyl acetate extract is evaporated to extractum under-0.04Mpa--0.06Mpa pressure, passes through vacuum drying then, and resulting dry thing is crushed to fine powder, promptly obtains the operable active bilobalide extract of the present invention.
Content of bilobalide is higher than 20% in the bilobalide extract of the present invention, and total lactone content is higher than 50%.
Treat in the capsule medicine of senile dementia in the present invention, described diluent is that one or more are selected from the diluent in Icing Sugar, anhydrous glucose, mannitol and the lactose.Preferably, described diluent is Icing Sugar, lactose, and lactose is most preferred.
Treat in the capsule medicine of senile dementia in the present invention, described binding agent is that one or more are selected from the binding agent in hypromellose, dextrin, Icing Sugar and the microcrystalline Cellulose.Preferably, described binding agent is microcrystalline Cellulose, dextrin, and dextrin is most preferred.
Treat in the capsule medicine of senile dementia in the present invention, described lubricant is that one or more are selected from the lubricant in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci and the microcrystalline silicon.Preferably, described lubricant is microcrystalline silicon, magnesium stearate, and magnesium stearate is most preferred.
Treat in the tablet medicine of senile dementia in the present invention, described diluent is that one or more are selected from the diluent in Icing Sugar, anhydrous glucose, microcrystalline Cellulose, mannitol and the lactose.Preferably, described diluent is microcrystalline Cellulose, lactose, and microcrystalline Cellulose is most preferred.
Treat in the tablet medicine of senile dementia in the present invention, described binding agent is that one or more are selected from the binding agent in hypromellose, dextrin, Icing Sugar and the microcrystalline Cellulose.Preferably, described binding agent is Icing Sugar, dextrin, and dextrin is most preferred.
Treat in the tablet medicine of senile dementia in the present invention, described disintegrating agent is that one or more are selected from the disintegrating agent in polyvinylpolypyrrolidone, carboxymethyl starch, starch and the hydroxypropyl starch.Preferably, described disintegrating agent is carboxymethyl starch, starch, and carboxymethyl starch is most preferred.
Treat in the tablet medicine of senile dementia in the present invention, described lubricant is that one or more are selected from the lubricant in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci and the microcrystalline silicon.Preferably, described lubricant is microcrystalline silicon, magnesium stearate, and magnesium stearate is most preferred.
This shows, when using the different dosage form of bilobalide extract preparation treatment senile dementia medicine of the present invention, can use required adjuvant various commonly used, as diluent, disintegrating agent, lubricant, binding agent etc., adopt conventional method of Chinese medicinal to be prepared into any peroral dosage form commonly used, as pill, powder, tablet, capsule, oral liquid etc.
[beneficial effect]
The medicine that the present invention treats senile dementia cures mainly that blood stasis due to qi deficiency, venation are smooth, hypophrenia due to the deficiency of marrow-reservoir, headache brain are dizzy, lip is dark and gloomy, look quietly, few vigorously of few words, or diseases such as restlessness, speech disturbance, inarticulateness.Modern medicine belongs to memory due to brain cell atrophy, the degeneration, understands, judges, calculates, directed, morning, moderate senile dementia disease that control weakens, sees above-mentioned disease person.
[description of drawings]
But Fig. 1 is the influence of explanation silver capsule to Hippocampus related gene expression in the naturally-aged rat brain.
[specific embodiment]
Below further set forth the beneficial effect of medicine of the present invention by the test example, these test examples have comprised the pharmaceutical test and the clinical observation on the therapeutic effect experiment of medicine of the present invention (but but to call silver capsule, silver diaphragm in the following text).
Test example 1: but the silver capsule is to the influence of normal mouse memory function
Test material
But medicine silver capsule, test Folium Ginkgo extract dry powder (Folium Ginkgo terpene lactones content 61.93%), provide by Sanjiangyuan Pharmaceutical Co., Ltd., Suizhou City, lot number: 20010510, be mixed with respectively with 1%CMC (carboxymethyl cellulose) during test: 4.5mg/ml, 2.25mg/ml and 1.13mg/ml concentration; Huperzine A-Zhulin Antun (huperzine A sheet), 50 μ g/ sheets, the product that pharmaceutical factory produces in the Henan bamboo grove all living creatures pharmacy joint stock company limited Henan, lot number: 001101, be mixed with 5.2 μ g/ml with 1%CMC (carboxymethyl cellulose); Tanakan (Folium Ginkgo extract sheet) 40mg/ sheet, the product that the general living pharmaceuticals industry of French Bo Fu-benefit company produces, import drugs registration certificate number: X19990156 is mixed with 1.6mg/ml with 1%CMC.
70 of animal Kunming mouses, male and female half and half, body weight are 18 ± 2 grams, and Beijing Vital River Experimental Animals Technology Co., Ltd. provides, animal licence numbering: SCXK11-00-0008.
Test method
Animal is divided into 6 groups at random, 10 of every treated animals, male and female half and half: matched group and model group (1%CMC, 10ml/kg); But silver capsule 45.0mg/kg group; But silver capsule 22.5mg/kg group; But silver capsule 11.3mg/kg group; Positive drug Huperzine A-Zhulin Antun 52 μ g/kg group.Be administered once every day, 10ml/kg, continuous 10 days.
In administration the 6th day, irritate stomach after 60 minutes, each treated animal was put into water maze 3 minutes, animal is swum out of automatically, trained continuously 5 days, observation is respectively organized the errors number of mice and is swum out of the time, carry out handling with last detection data, relatively the difference between each treated animal with statistical data.
Result of the test
After the administration 10 days, but silver capsule 45.0mg/kg, 22.5mg/kg dosage treated animal in the watermaze protocol auto-controller 3 minutes errors number and swim out of the time and model group relatively has notable difference (P＜0.05).Its result of the test sees Table 1.
But table 1. silver capsule is to the influence of normal mouse memory function (meansigma methods ± SD)
| Grouping | Dosage (mg/kg) | Number of animals (n) | Errors number (inferior) | Swim out of the time (second) |
| Matched group | ????10 | ?36.40±12.31 | ?122.30±64.24 | |
| Model group | ????10 | ?21.40±12.00* | ?60.00±64.88* | |
| But silver Capsules group | ????45.0 | ????10 | ?22.90±13.22* | ?86.20±75.21 |
| But silver Capsules group | ????22.5 | ????10 | ?28.00±13.77 | ?123.70±73.09 |
| But silver Capsules group | ????11.3 | ????10 | ?24.30±11.75* | ?61.10±64.41* |
| The Huperzine A-Zhulin Antun group | ????0.052 | ????10 | ?23.20±12.29* | ?75.90±72.53 |
Annotate: * and model group be P＜0.05 relatively
Conclusion
Experimental result shows: experimental result shows, the errors number of control animals is 36.40 ± 12.31, but the large, medium and small dosage group of silver capsule is respectively 21.40 ± 12.00,22.90 ± 13.22,28.00 ± 13.77, and the Huperzine A-Zhulin Antun group is 24.30 ± 11.75, and the Tanakan group is 23.20 ± 12.29.The control animals time of swimming out of is 122.30 ± 64.24 seconds, but the large, medium and small dosage group of silver capsule is respectively 60.00 ± 64.88,86.20 ± 75.21,123.70 ± 73.28, the Huperzine A-Zhulin Antun group is 61.10 ± 64.41, the Tanakan group is 75.90 ± 72.53, learn by statistics and handle, but silver capsule 45.0mg/kg, 22.5mg/kg dosage group, relatively there were significant differences for Tanakan group and matched group, but prompting silver capsule can obviously reduce mouse wrong times and the time is swum out of in shortening, and has a statistically-significant difference, but prompting silver capsule has the effect that increases the mouse memory function, and a certain amount of effect relationship is arranged.
Test example 2: but the silver capsule is to the influence of naturally-aged rat
But this embodiment illustrates the influence of silver capsule gastric infusion to memory of naturally-aged rat and Hippocampus related gene expression
Test material
But medicine silver capsule, Folium Ginkgo extract is used in test, and its Folium Ginkgo terpene lactones content 61.93% is provided by Sanjiangyuan Pharmaceutical Co., Ltd., Suizhou City, lot number: 20010510, be mixed with respectively with 1%CMC (carboxymethyl cellulose) during test: 3.2mg/ml, 1.6mg/ml and 0.8mg/ml concentration; Tanakan (Folium Ginkgo extract sheet) 40mg/ sheet, the general living pharmaceuticals industry of French Bo Fu-benefit company, import drugs registration certificate number: X19990156,1%CMC is mixed with 1.1mg/ml.
3 monthly age of animal 10 of SD rats, male and female half and half; 50 of 18 monthly age SD rats, male and female half and half.Animal licence numbering: SCXK11-00-0006.
Test method:
Geriatric animals (18 monthly age) is divided into 5 groups at random, i.e. aged control group (1%CMC); But silver capsule 45mg/kg group; But silver capsule 22.5mg/kg group; But silver capsule 11.3mg/kg group; Positive drug Huperzine A-Zhulin Antun 52 μ g/kg group; Tanakan 11mg/kg group; Young group (3 monthly age), 10 every group.Press 10ml/kg volume gastric infusion, once a day, continuous 6 weeks.
Geriatric animals is put into Morris water maze system training 3 minutes with young treated animal after respectively organizing 5 weeks of administration, trains continuously 5 days.The 5th day animal incubation period at the Morris water maze is measured and write down to each treated animal.In training process, still continue administration.
After 6 weeks of administration, each treated animal broken end is got brain, the hippocampal tissue of peeling off in the brain is carried out biochemical measurement, observes the biochemical indicator of each treated animal.
Data are carried out statistical procedures, comparable group differences (t check).
Result of the test
1. but the silver capsule is to the influence of memory function
Be 18.30 ± 15.55 seconds the incubation period of young treated animal, and old group is 89.60 ± 58.38 seconds, but the large, medium and small dosage group of silver capsule be respectively 24.10 ± 22.09 seconds, 33.70 ± 39.10 seconds, 44.20 ± 51.91 seconds, the Tanakan group is 28.10 ± 23.87 seconds.Learn by statistics and handle, organize comparison with the youth, aged control animal Morris water maze obviously prolongs (P＜0.01) incubation period, shows that naturally-aged rat space identification ability goes down; With aged control relatively, but three dosage treated animals of silver capsule obviously shorten (P＜0.05～0.01) incubation period, but can point out the silver capsule that the rat memory of naturally-aged is descended thus the improvement effect are arranged.Its result of the test sees the following form 2.
But table 2. silver capsule is to the influence of naturally-aged memory function (meansigma methods ± SD)
| Grouping | Dosage (mg/kg) | Number of animals (n) | Incubation period (second) |
| Young group | ????10 | ????18.30±15.55 | |
| Aged control | ????10 | ????89.60±58.38 ## | |
| But silver Capsules group | ????32 | ????10 | ????24.10±22.09** |
| But silver Capsules group | ????16 | ????10 | ????33.70±39.10* |
| But silver Capsules group | ????8 | ????10 | ????44.20±51.91* |
| The Tanakan group | ????11 | ????10 | ????28.10±23.87** |
Annotate: organize comparison with the youth:
##P＜0.01; Compare with aged control: * P＜0.05, P＜0.01
2. but the silver capsule is to the influence of Hippocampus related gene expression in the brain
The method of using immunodot test has been observed the expression of CREB, PI3K, ERAB, Cyt-C and GSK-3 β.CREB (c-AMP Response Element Binding Protein, the c-AMP response element binding protein) is unphosphorylated nuclear factor, can promote some to have the gene expression of keeping the neurocyte survival, so its increased response helps neuron survival.PI3K (Phosphatidylinositol 3 ' Kinase, phosphatidyl gallbladder alcohol 3 ' kinases) is another path in the transduction of neurocyte survival signal, and its increased response also helps neuronic survival.ERAB (Endoplasmic-Related A β binding Protein, endoplasmic reticulum is relevant conjugated protein) just produces neurotoxicity with A β (β-Amyloid, beta amyloid peptide) combination, and increased response is to the toxic effect of neurocyte.Cyt-C (Cytochrome C, cytochrome C) and apoptosis inducing factor etc. are mitochondrial inclusion, express to strengthen making neuronal apoptosis.GSK-3 β (Glucogen Synthetic Kinase-3 β, glycogen synthesizes kinases 3 β, participates in the generative process of acetylcholine indirectly, and its increased response shows the generation that is used for acetylcholine.
Experimental result shows: CREB, PI3K, GSK-3 beta response in the young group rat hippocampus are stronger, a little less than ERAB, the Cyt-C reaction; Old group CREB, PI3K, GSK-3 beta response a little less than, ERAB, Cyt-C reaction is stronger; But three dosage groups of silver capsule and Tanakan group index of correlation all have improvement in various degree, this medicine has enhanced effect to gene C REB, the PI3K that helps the neurocyte survival, the GSK-3 β that promotes acetylcholine to generate there is potentiation, gene ERAB, the Cyt-C that causes nerve cell death had inhibitory action.Promote the effect that hippocampal neurons survival and acetylcholine generate but point out the silver capsule to have thus.But the silver capsule is to the visible accompanying drawing 1 of the influence of Hippocampus related gene expression in the naturally-aged rat brain.
Conclusion
Experimental result shows: but the silver capsule can improve the memory function of naturally-aged rat, and have survival of promotion hippocampal neurons and acetylcholine life to act as.
Claims (14)
1, a kind of capsule medicine for the treatment of senile dementia is characterized in that this capsule medicine forms (by weight) by following component:
Bilobalide extract 5-7 part
Diluent 5-8 part
Binding agent 7-9 part
Lubricant 0.05-0.15 part
2, capsule medicine according to claim 1 is characterized in that this capsule medicine forms (by weight) by following component:
6 parts of bilobalide extracts
6 parts of diluent
8 parts of binding agents
0.1 part of lubricant
3, a kind of tablet medicine for the treatment of senile dementia is characterized in that this tablet medicine forms (by weight) by following component:
Bilobalide extract 5-7 part
Diluent 8-12 part
Binding agent 1-3 part
Disintegrating agent 1-3 part
Lubricant 0.05-0.15 part
4, tablet medicine according to claim 3 is characterized in that this tablet medicine forms (by weight) by following component:
6 parts of bilobalide extracts
10 parts of diluent
2 parts of binding agents
2 parts of disintegrating agents
0.1 part of lubricant
5,, it is characterized in that at the extract of bilobalide described in this medicine be according to comprising that the method for following each processing step obtains according to the described medicine of arbitrary claim among the claim 1-4:
(1) exsiccant ginkgo leaf powder is broken to sheet, place in the reflux, extract, jar, add concentration 40-60 volume % ethanol, its alcoholic solution consumption be make a living by weight dose 5-10 doubly, temperature 75-85 ℃ of following reflux, extract, 3-5 time, each 1-3 hour, need to filter after each the extraction, the merging of these filtrates obtains extracting solution
(2) described extracting solution≤-0.065Mpa pressure under concentrating under reduced pressure, reclaim its ethanol, this concentrating until the concentrated solution that obtains not having alcohol,
(3) add deionized water and return molten above-mentioned concentrated solution, return molten solution amount and generally be make a living by weight dose 6-10 doubly, return the molten solution left standstill that obtains, filtration,
(4) medicinal liquid that obtains after filtering adsorbs by nonpolar class macroporous resin column with the flow velocity of 1-1.5 times of column volume per hour, the weight ratio of crude drug amount and resin demand=1: 0.8-2.0, absorption is back with 1-4 times of column volume deionized water rinsing, then, with the about 10-20 volume of about 2-6 times column volume % ethanol water eluting, discard eluent, reuse 2-5 times column volume 60 volume % ethanol water eluting earlier, collect this eluent
(5) with the eluent collected≤-be evaporated to the extractum that does not have alcohol under the 0.065Mpa pressure, add ethyl acetate extraction 2-5 time then, adding the ethyl acetate total amount is in 0.5-1.0 times of volume of crude drug amount, the combined ethyl acetate extract, reuse mineral acid or organic acid sodium salt solution washing or do not wash
(6) acetic acid ethyl acetate extract is evaporated to extractum under-0.04Mpa--0.06Mpa pressure, passes through vacuum drying then, and resulting dry thing is crushed to fine powder, promptly obtains the operable active bilobalide extract of the present invention.
6, medicine according to claim 5 is characterized in that the content of bilobalide of described bilobalide extract is higher than 20%, and total lactone content is higher than 50%.
7, medicine according to claim 5 is characterized in that described mineral acid sodium salt is sodium sulfite, Chile saltpeter or sodium dihydrogen phosphate, and described organic acid sodium salt is sodium acetate, sodium citrate or Disodium oxalate..
8,, it is characterized in that described diluent is that one or more are selected from the diluent in Icing Sugar, anhydrous glucose, mannitol and the lactose according to the described capsule medicine of arbitrary claim among the claim 1-2.
9,, it is characterized in that described binding agent is that one or more are selected from the binding agent in hypromellose, dextrin, Icing Sugar and the microcrystalline Cellulose according to the described capsule medicine of arbitrary claim among the claim 1-2.
10,, it is characterized in that described lubricant is that one or more are selected from the lubricant in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci and the microcrystalline silicon according to the described capsule medicine of arbitrary claim among the claim 1-2.
11,, it is characterized in that described diluent is that one or more are selected from the diluent in Icing Sugar, anhydrous glucose, microcrystalline Cellulose, mannitol and the lactose according to the described tablet medicine of arbitrary claim among the claim 3-4.
12,, it is characterized in that described binding agent is that one or more are selected from the binding agent in hypromellose, dextrin, Icing Sugar and the microcrystalline Cellulose according to the described tablet medicine of arbitrary claim among the claim 3-4.
13,, it is characterized in that described disintegrating agent is that one or more are selected from the disintegrating agent in polyvinylpolypyrrolidone, carboxymethyl starch, starch and the hydroxypropyl starch according to the described tablet medicine of arbitrary claim among the claim 3-4.
14,, it is characterized in that described lubricant is that one or more are selected from the lubricant in stearic acid, magnesium stearate, calcium stearate, Pulvis Talci and the microcrystalline silicon according to the described tablet medicine of arbitrary claim among the claim 3-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03121979 CN1451382A (en) | 2003-04-21 | 2003-04-21 | Medicine for treating senile dementia and preparing process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03121979 CN1451382A (en) | 2003-04-21 | 2003-04-21 | Medicine for treating senile dementia and preparing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1451382A true CN1451382A (en) | 2003-10-29 |
Family
ID=29222852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03121979 Pending CN1451382A (en) | 2003-04-21 | 2003-04-21 | Medicine for treating senile dementia and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1451382A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101375996B (en) * | 2008-09-27 | 2010-12-08 | 曹开镛 | Brain-tonifying and intelligence-raising formulation and preparation method thereof |
| CN114272237A (en) * | 2022-01-21 | 2022-04-05 | 苏州大学附属第一医院 | Ginkgo biloba extract for treating osteoarthritis |
-
2003
- 2003-04-21 CN CN 03121979 patent/CN1451382A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101375996B (en) * | 2008-09-27 | 2010-12-08 | 曹开镛 | Brain-tonifying and intelligence-raising formulation and preparation method thereof |
| CN114272237A (en) * | 2022-01-21 | 2022-04-05 | 苏州大学附属第一医院 | Ginkgo biloba extract for treating osteoarthritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN1210047C (en) | Medicine for treating common cold and preparation method | |
| CN1840043A (en) | Pharmaceutical composition for treating depression, its preparation method and application | |
| CN1224383C (en) | Blood sugar reducing compound | |
| CN110916033A (en) | Beverage for reducing uric acid and preparation method thereof | |
| CN102935100A (en) | Preparation method and applications of queen lagerstroemia folium apocyni veneti general flavones | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1683358A (en) | Process for extracting total flavone from stem and leaf of scutellaria | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN110123858A (en) | A kind of application of Aplotaxis auriculata essential oil | |
| CN1857622A (en) | Medicine composition and preparation containing effective components of gastrodia tuber and Chuanxiong rhizome | |
| CN1943570A (en) | Use of opc in preparing medicine for treating and preventing senile dementia | |
| CN1451382A (en) | Medicine for treating senile dementia and preparing process thereof | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| CN103800596A (en) | Areca fruit total phenol extractive as well as preparation method and application thereof | |
| CN1810268A (en) | Apoplexy treating medicine composition | |
| CN101129972A (en) | Traditional Chinese medicine composition, preparation method and use of the same | |
| CN1830458A (en) | New use of tribulus terrestris extraction | |
| CN1246326C (en) | Pineapple flavonoid glycoside compound and its use | |
| CN1313499C (en) | Sargassum polysaccharide, its preparation method and use | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN1182864C (en) | Medicine for vascular denmentia disease and preparation method | |
| CN1272018C (en) | Application of liquorice glycoside in preparing drugs for preventing and/or treating depression | |
| CN110279748A (en) | A kind of application of Cortex Magnoliae Officinalis essential oil | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |